Chemoprevention

• 

  Subject Areas on Research

  • Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. 
  • Advances and failures in preventing perinatal human immunodeficiency virus infection. 
  • Aerosol and other novel administrations for prevention and treatment of invasive aspergillosis. 
  • An Infection Control Program for a 2009 influenza A H1N1 outbreak in a university-based summer camp. 
  • Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. 
  • Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. 
  • Chemoprevention of pancreatic cancer: ready for the clinic? 
  • Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. 
  • Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. 
  • Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines. 
  • Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. 
  • Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity? 
  • Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective? 
  • ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. 
  • Early diagnosis and prevention of sporadic colorectal cancer. 
  • Early prostate cancer: prevention, treatment modalities, and quality of life issues. 
  • Echinocandins: a wealth of choice--how clinically different are they? 
  • Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. 
  • Evaluation and management of fungal infections in immunocompromised patients. 
  • Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. 
  • Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. 
  • Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention. 
  • Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. 
  • Intermittent preventive treatment for malaria in infants: moving forward, cautiously. 
  • Invasive mould infections: a multi-disciplinary update. 
  • Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. 
  • Low incidence of symptomatic thromboembolic events after total ankle arthroplasty without routine use of chemoprophylaxis. 
  • Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). 
  • Malaria: a rising incidence in the United States. 
  • Overview of treatment options for invasive fungal infections. 
  • Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. 
  • Partnerships Between a University-Affiliated Clinic and Community-Based Organizations to Reach Black Men Who Have Sex With Men for PrEP Care. 
  • Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design. 
  • Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. 
  • Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. 
  • Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. 
  • Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. 
  • Prevention of lung cancer: summary of published evidence. 
  • Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply. 
  • Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. 
  • Reasons for Refusal of Newborn Vitamin K Prophylaxis: Implications for Management and Education. 
  • Reply to Verweij et al. 
  • Statins and cancer risk: what do we know and where do we go from here? 
  • The epidemiology and diagnosis of invasive candidiasis among premature infants. 
  • The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis? 
  • The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. 
  • Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. 
  • Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial. 
• 

  Keywords of People

  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Moorman, Patricia Gripka, Professor in Family Medicine and Community Health, Duke Cancer Institute
  • O'Meara, Wendy P, Associate Professor of Medicine, Medicine, Infectious Diseases
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Tsalik, Ephraim, Associate Professor of Medicine, Molecular Genetics and Microbiology